All the latest news

Evolus investors frown as FDA declines to approve Botox rival

(Reuters) - U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.

Read The Rest at Reuters: Health News


Please Insert Your Name Please Insert Your E-Mail Please Write Your Comment Error Happened